Proteasome inhibitor mg‑132 enhances histone deacetylase inhibitor saha‑induced cell death of chronic myeloid leukemia cells by an ros‑mediated mechanism and downregulation of the bcr‑abl fusion protein

Zhou,Wenjing; Zhu,Weiwei; Ma,Liya; Xiao,Feng; Qian,Wenbin

doi:10.3892/ol.2015.3665

Proteasome inhibitor mg‑132 enhances histone deacetylase inhibitor saha‑induced cell death of chronic myeloid leukemia cells by an ros‑mediated mechanism and downregulation of the bcr‑abl fusion protein

Authors:
- Wenjing Zhou
- Weiwei Zhu
- Liya Ma
- Feng Xiao
- Wenbin Qian
View Affiliations

Affiliations: Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: September 2, 2015 https://doi.org/10.3892/ol.2015.3665
Pages: 2899-2904

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recently, there has been progress in the treatment of chronic myeloid leukemia (CML). However, novel therapeutic strategies are required in order to address the emerging problem of imatinib resistance. Histone deacetylase inhibitors (HDACi) and proteasome inhibitors are promising alternatives, and may be amenable to integration with current therapeutic approaches. However, the mechanisms underlying the interaction between these two agents remain unclear. The present study assessed the cytotoxic effect of the HDACi, suberoylanilide hydroxamic acid (SAHA), in combination with the proteasome inhibitor, MG‑132, in imatinib‑sensitive K562 and imatinib‑resistant K562G cells, and investigated the mechanism underlying this effect. Cell viability was measured using the 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide method and protein expression levels were determined by western blotting. Reactive oxygen species (ROS) generation levels were observed under a fluorescence microscope The results indicated that SAHA and MG‑132 act in a synergistic manner to induce cell death in K562 and K562G cells. This effect was associated with Bcr‑Abl downregulation and the production of ROS. Notably, the ROS scavenger, N‑acetyl‑L‑cysteine, almost fully reversed the cell death and Bcr‑Abl downregulation that was induced by the combination of SAHA and MG‑132. By contrast, the pan‑caspase inhibitor, z‑VAD‑fmk, only partially reversed the cell death induced by these two drugs in CML cells. These results indicated that increased intracellular ROS levels are important in the induction of cell death and the downregulation of Bcr‑Abl. In conclusion, the present results suggested that combined SAHA and MG‑132 may be a promising treatment for CML.

View Figures

View References

1	Yang C, Yang J, Sun M, Yan J, Meng X and Ma T: Alantolactone inhibits growth of K562/adriamycin cells by downregulating Bcr/Abl and P-glycoprotein expression. IUBMB Life. 65:435–444. 2013. View Article : Google Scholar : PubMed/NCBI
2	Melo JV and Chuah C: Novel agents in CML therapy: Tyrosine kinase inhibitors and beyond. Hematology Am Soc Hematol Educ Program. 427–435. 2008. View Article : Google Scholar : PubMed/NCBI
3	Carafa V, Nebbioso A and Altucci L: Histone deacetylase inhibitors: Recent insights from basic to clinical knowledge & patenting of anti-cancer actions. Recent Pat Anticancer Drug Discov. 6:131–145. 2011. View Article : Google Scholar : PubMed/NCBI
4	Lemal R, Ravinet A, Moluçon-Chabrot C, Bay JO and Guièze R: Histone deacetylase inhibitors in the treatment of hematological malignancies. Bull Cancer. 98:867–878. 2011.(In French). PubMed/NCBI
5	O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, et al: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 24:166–173. 2006. View Article : Google Scholar : PubMed/NCBI
6	Kelly WK and Marks PA: Drug insight: Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol. 2:150–157. 2005. View Article : Google Scholar : PubMed/NCBI
7	Yamamoto S, Tanaka K, Sakimura R, Okada T, Nakamura T, Li Y, Takasaki M, Nakabeppu Y and Iwamoto Y: Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res. 28:1585–1591. 2008.PubMed/NCBI
8	Nimmanapalli R, Fuino L, Stobaugh C, Richon V and Bhalla K: Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood. 101:3236–3239. 2003. View Article : Google Scholar : PubMed/NCBI
9	Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ and Cleveland JL: Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood. 110:313–322. 2007. View Article : Google Scholar : PubMed/NCBI
10	Fiskus W, Wang Y, Joshi R, Rao R, Yang Y, Chen J, Kolhe R, Balusu R, Eaton K, Lee P, et al: Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res. 14:6106–6115. 2008. View Article : Google Scholar : PubMed/NCBI
11	Yu C, Rahmani M, Conrad D, Subler M, Dent P and Grant S: The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood. 102:3765–3774. 2003. View Article : Google Scholar : PubMed/NCBI
12	Guo N and Peng Z: MG132, A proteasome inhibitor, Induces apoptosis in tumor cells. Asia Pac J Clin Oncol. 9:6–11. 2013. View Article : Google Scholar : PubMed/NCBI
13	Jagani Z, Song K, Kutok JL, Dewar MR, Melet A, Santos T, Grassian A, Ghaffari S, Wu C, Yeckes-Rodin H, et al: Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors. Cancer Res. 69:6546–6555. 2009. View Article : Google Scholar : PubMed/NCBI
14	Miller CP, Ban K, Dujka ME, McConkey DJ, Munsell M, Palladino M and Chandra J: NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood. 110:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
15	Tong Y, Liu YY, You LS and Qian WB: Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro. Acta Pharmacol Sin. 33:542–550. 2012. View Article : Google Scholar : PubMed/NCBI
16	Park WH and Kim SH: MG132, a proteasome inhibitor, induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion. Oncol Rep. 27:1284–1291. 2012.PubMed/NCBI
17	Heaney NB and Holyoake TL: Therapeutic targets in chronic myeloid leukaemia. Hematol Oncol. 25:66–75. 2007. View Article : Google Scholar : PubMed/NCBI
18	Marks PA, Richon VM and Rifkind RA: Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 92:1210–1216. 2000. View Article : Google Scholar : PubMed/NCBI
19	Gorre ME and Sawyers CL: Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol. 9:303–307. 2002. View Article : Google Scholar : PubMed/NCBI
20	Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J and Sawyers CL: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2:117–125. 2002. View Article : Google Scholar : PubMed/NCBI
21	Sankari SL, Masthan KM, Babu NA, Bhattacharjee T and Elumalai M: Apoptosis in cancer-an update. Asian Pac J Cancer Prev. 13:4873–4878. 2012. View Article : Google Scholar : PubMed/NCBI
22	Azad MB, Chen Y and Gibson SB: Regulation of autophagy by reactive oxygen species (ROS): Implications for cancer progression and treatment. Antioxid Redox Signal. 11:777–790. 2009. View Article : Google Scholar : PubMed/NCBI
23	Ling LU, Tan KB, Lin H and Chiu GN: The role of reactive oxygen species and autophagy in safingol-induced cell death. Cell Death Dis. 2:e1292011. View Article : Google Scholar : PubMed/NCBI
24	Stein SJ and Baldwin AS: NF-κB suppresses ROS levels in BCR-ABL(+) cells to prevent activation of JNK and cell death. Oncogene. 30:4557–4566. 2011. View Article : Google Scholar : PubMed/NCBI
25	Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M and Grant S: HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW.2449 in imatinib. sensitive or. resistant BCR/ABL+leukemia cells in vitro and in vivo. Clin Cancer Res. 17:3219–3232. 2011. View Article : Google Scholar : PubMed/NCBI